Literature DB >> 35730620

Myocardial Injury in Patients With Acute and Subacute Chagas Disease in the Brazilian Amazon Using Cardiovascular Magnetic Resonance.

Katia do Nascimento Couceiro1, Jessica Vanina Ortiz1,2, Mônica Regina Hosannah da Silva E Silva1, Débora Raysa Teixeira de Sousa1, Rubens Celso Andrade1, Alba Regina Jorge Brandão1, Rômulo Freire de Morais1, Susan Smith Doria1, Rafael Almeida Fonseca3, Paula Rita Leite da Silva1, Fabio Fernandes4, Maria das Graças Vale Barbosa Guerra1, Carlos Eduardo Rochitte3, João Marcos Bemfica Barbosa Ferreira1,2, Jorge Augusto de Oliveira Guerra1.   

Abstract

Background Chagas disease is a neglected tropical disease that is still considered a global health emergency. In the Amazon region, most of the reports are of acute cases that are associated with oral transmission. This study aimed to evaluate myocardial injury in patients with acute Chagas disease before and after treatment. Methods and Results We evaluated 23 patients with acute Chagas disease in 3 different stages of progression. Group 1 had 12 patients evaluated during the acute phase, at the time of diagnosis, and 1 year after treatment, and Group 2 had 11 patients in the late postacute phase who were evaluated 5.2 years on average after diagnosis and treatment. ECGs with the Selvester score, 24-hour Holter exam, and cardiovascular magnetic resonance imaging were performed. The mean age of the 23 patients was 44.3±18.9 years, and they were mostly men (15/65.24%) from Amazonas state (22/95.6%). In 69.6% (n=16) of the patients, some ECG alterations were found, the most frequent being left anterior fascicular block and ventricular repolarization. In Group 1, the 24-hour Holter exam showed atrial tachycardia in 3 (25%) patients and ventricular extrasystoles in 2 (16.7%) patients. In Group 2, 1 patient had ventricular extrasystoles. Myocardial injury was observed in 7 patients (58.3%) at the acute phase and in 5 (50%) patients at the 1-year follow-up in Group 1 and in 2 (18.2%) patients in Group 2. Conclusions This article describes, for the first time, myocardial injury shown by cardiovascular magnetic resonance imaging in a group of patients with acute Chagas disease and reveals the importance of early detection and follow-up of the cardiac impairment in these patients.

Entities:  

Keywords:  Brazilian Amazon; acute Chagas disease; myocardial injury

Mesh:

Year:  2022        PMID: 35730620      PMCID: PMC9333391          DOI: 10.1161/JAHA.121.021806

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   6.106


acute Chagas disease Chagas disease group 1 group 1 with 1‐year follow‐up group 2 late gadolinium enhancement myocardial fibrosis Selvester score

Clinical Perspective

What Is New?

The prevalence of Chagas disease in western Amazonia has been growing significantly through the oral route transmission and attributed to the consumption of contaminated food. Acute Chagas disease can cause myocardial injury that can be detected by cardiovascular magnetic resonance with potential prognostic and diagnostic value.

What Are the Clinical Implications?

A low‐cost and easily accessible tool such as the Selvester score could be an alternative in the detection of early myocardial injury in acute Chagas disease. Chagas disease (CD) is a neglected tropical disease that is still considered a global health emergency. It is estimated that >7 million people are infected with Trypanosoma cruzi worldwide, and >70 million people live in areas with a constant risk of transmission. , In Latin America, the disease is endemic in 21 countries, including Brazil, where it is estimated that more than a million people are living with CD, and this results in ≈4000 deaths every year. In the Amazon region, most reports are of acute cases associated with oral transmission that has occurred as the result of the ingestion of juices made from palm fruits (eg, açaí berry, palm tree wine, sugar cane, and guava juices). Clinically, these acute cases may present nonspecific symptoms and for which treatment with benznidazole (Rochagan) is able to achieve 90% efficacy. Chagas cardiomyopathy is the main cause of morbidity and mortality, and myocardial injury can be precisely detected by cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE) technique. However, this condition is mostly described in the chronic phase of CD. CMR is an imaging technique that is a significant technological development widely used in the diagnosis, monitoring, and treatment of cardiovascular diseases, especially in cardiomyopathies, with regard to diagnostic and prognostic differentiation. Postinflammatory myocardial injury can be safely identified by CMR with delayed enhancement, which is as an important predictor of arrhythmia and sudden death in several nonischemic cardiomyopathies, such as hypertrophic cardiomyopathy and chronic chagasic cardiomyopathy, and may be useful in risk stratification in patients with CD. To our knowledge, there are no studies that assessed the presence of myocardial injury by CMR involving a series of cases of acute CD (ACD) or with follow‐up evaluation after treatment. In addition, in the Amazon region, the aspects of the cardiac involvement of the disease, such as the evaluation of myocardial injury and cardiac arrhythmias, are not well known. Thus, the aim of this study was to investigate the presence and magnitude of myocardial injury in autochthonous patients with CD in the acute and posttreatment phases in the Brazilian Amazon using CMR.

Methods

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Study Design and Patient Population

This longitudinal study was carried out at the CD outpatient clinic of the Tropical Medicine Foundation Dr Heitor Vieira Dourado and followed up autochthonous patients from the western Amazon who were diagnosed with ACD. Three groups at different stages of disease progression were included: group 1 (G1) with 12 patients with ACD evaluated before the start of treatment (G1) and with 1 year follow‐up (G1‐FU) after the end of treatment with benznidazole and group 2 (G2) with 11 late postacute patients evaluated 5.2 years on average after diagnosis and treatment. All patients were diagnosed by direct parasitological examination and a thick smear test and treated with benznidazole (Rochagan), 5 to 7 mg/kg for 60 days according to the II Brazilian Consensus on Chagas Disease, 2005 and 2015. ,

ECG Analysis and Dynamic Electrocardiography (24‐Hour Holter Exam)

All patients underwent a standard 12‐lead ECG (10 mm/mV and 25 mm/s). The ECG analysis was performed blindly by 2 experienced cardiologists, following the criteria established in the Brazilian Electrocardiogram Guidelines. The evaluation of the Selvester score (SS) followed the recommendations established by Loring et al, in which each point was designed to correspond to ≈3% of left ventricular injury. The patients underwent prolonged ECG monitoring (24‐hour Holter exam) to allow the detection and reproduction of arrhythmia tracings for a longer period.

Selvester QRS Score

The SS is a 12‐lead ECG analysis in which the QRS complex is adjusted for sex and age in the parameters of duration and amplitude (millivolt). Each column of the score table represents an ECG alteration (right bundle branch block, left anterior fascicular block, left ventricular hypertrophy, left bundle branch block) or no alteration, and the score is recorded for each of these possibilities. The percentage of left ventricular scars estimated by ECG was calculated by multiplying the overall QRS score by 3 because each point in the score corresponds to 3% of total mass of the left ventricle (LV). Afterward, the differences in points and percentages obtained by the 2 observers were compared during a meeting, during which no disagreements were detected.

CMR Imaging and Analysis

CMR imaging with LGE was performed on all selected patients using a Philips Ingenia 1.5 T Scanner. The functional evaluation used conventional cine resonance using steady‐state free precession gradient echo. Tissue characterization assessed the presence of myocardial edema using T2‐weighted sequence with fat suppression and the presence of myocardial fibrosis (MF) by LGE with 2‐dimensional and 3‐dimensional acquisitions. The intravenous contrast material used was gadobutrol (0.1 mmol/kg), a gadolinium‐based contrast agent. Data analysis was performed by a specialist in cardiac imaging with >5 years of experience in CMR analysis. A quantitative functional assessment was carried out to obtain the structural measurements of diastolic and systolic diameters of the LV, diastolic wall thickness, anterior systolic diameter of the left atrium, left atrial volume by biplane measurements, mean lateral diameter of the right ventricle, and the presence of pericardial effusion and the functional measurements of LV and right ventricle diastolic and systolic volumes and ejection fraction. In LGE, image locations by the American Heart Association segmentation, degree of transmurality, pattern, and amount of LGE in grams and as a percentage of LV mass were measured. Quantitative measures of LGE used as specialized and dedicated software using a threshold method with a 5‐SD cutoff (pixel intensities 5 SDs above the normal myocardium were considered as LGE).

Statistical Analysis

Clinical and epidemiological data were organized using the Excel 2016 program and analyzed using the SPSS 28 IBM software. For categorical variables, the Fisher exact test was used, and the results are presented in tables with absolute and relative frequencies. The distribution of continuous variables was tested for normality using the Kolmogorov–Smirnov test. For those with normal distribution, the paired Student t test was used with the results presented as mean±SD. To compare the percentage of LGE, the Fisher exact test was used. The correlation between the score of the SS and LGE (percentage in mass LV) was done using the Spearman correlation. A 95% CI was assumed for all statistical tests, and the results were considered statistically significant when P<0.05.

Ethical Considerations

This study is also part of a research funding call (No. 30/2013) issued by Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM/AM) and was approved by the Research Ethics Committee of Amazonas State University (Manaus, AM, Brazil) under the approval number 31812914.9.0000.5016/923.701, December 2014. It was also supported by a previous call and approved by the Human Research Ethics Committee of the Fundação de Medicina Tropical Dr Heitor Vieira Dourado (FMTHVD) on March 7, 2007, under number 1836, Certification number 027.0.114.000‐06, and carried out in accordance with Resolution 466/12 of the Brazilian National Health Council and the ethical guidelines of the 1975 Declaration of Helsinki. All participants signed an informed consent form approved by the Research Ethics Committee of the Tropical Medicine Foundation Dr Heitor Vieira Dourado, Manaus, AM, Brazil, under the approval number 66077017.8.0000.0005/2.043.174 in May 2017.

Results

Baseline Characteristics

We included 23 patients whose average age was 44.3±18.9 years. The majority were men (15/65.24%) from the state of Amazonas (22/95.6%) and had an epidemiological history of acute oral disease (18/78.3%). In 16 (69.5%) patients, 2 T. cruzi strains (TcI and TcIV) were identified, with a predominance of 13 (81.2%) for the TcIV strain (Table 1). All patients were asymptomatic from the cardiovascular point of view.
Table 1

Baseline Characteristics of Patients With Acute and Subacute Chagas Disease

VariablesTotal (N=23)G1 (n=12)G2 (n=11) P value
Age, y44.3±18.947.6±23.240.6±12.90.392*
Sex0.027
Female8 (34.8)7 (58.3)1 (9.1)
Male15 (65.2)5 (41.7)10 (90.9)
Origin, state1.000
Amazonas22 (95.7)11 (91.7)11 (100)
Roraima1 (4.3)1 (8.3)0
Transmission0.155
Oral18 (78.3)11 (91.7)7 (63.7)
Vectorial5 (21.7)1 (8.3)4 (36.3)
T. cruzi DTU161061.000
TcI3 (18.8)2 (20)1 (16.7)
TcIV13 (81.2)8 (80)5 (83.3)

Data are provided as mean±SD, number, or number (percentage). DTU indicates discrete type unit; G1, group 1; G2, group 2; and T. cruzi, Trypanosoma cruzi.

Unpaired Student t test.

Fisher exact test.

Baseline Characteristics of Patients With Acute and Subacute Chagas Disease Data are provided as mean±SD, number, or number (percentage). DTU indicates discrete type unit; G1, group 1; G2, group 2; and T. cruzi, Trypanosoma cruzi. Unpaired Student t test. Fisher exact test.

ECG Analysis

The ECG was abnormal in 7/12 (58.3%) patients in G1, in 5/10 (50%) patients in G1‐FU, and in 4/11 (36.4%) patients in G2. The alterations found most frequently were left anterior fascicular block and ventricular repolarization alteration in 21.7% of patients. No alterations in ventricular repolarization were found in these patients after 1 year of follow‐up (Table 2).
Table 2

Alterations in the ECG and 24‐Hour Holter Exam in Patients With Acute and Subacute Chagas Disease

VariablesG1 (n=12)G1‐FU (n=10) P value
ECG
Ventricular repolarization alteration3 (25)
Left anterior fascicular block2 (16.7)3 (25)0.070*
Atrial fibrillation1 (8.3)1 (8.3)
Pre‐excitation1 (8.3)1 (8.3)
24‐h Holter exam
Ventricular extrasystoles3 (25)
Paroxysmal supraventricular tachycardia3 (25)
QRS Selvester score17.7±11.811.1±6.90.057

Data are provided as mean±SD or number (percentage). G1 indicates group 1; and G1‐FU, group 1 with 1‐year follow‐up.

Fisher exact test.

Paired Student t test.

Alterations in the ECG and 24‐Hour Holter Exam in Patients With Acute and Subacute Chagas Disease Data are provided as mean±SD or number (percentage). G1 indicates group 1; and G1‐FU, group 1 with 1‐year follow‐up. Fisher exact test. Paired Student t test.

Dynamic Electrocardiography (24‐Hour Holter Exam)

Dynamic electrocardiography (24‐hour Holter exam) in the G1 patients demonstrated the presence of isolated and monomorphic ventricular ectopic in 2 (16.7%) patients, supraventricular arrhythmias of the type unsupported supraventricular tachycardia (atrial tachycardia) in 3 (25%) patients, preventricular excitation in 1 (8.3%) patient, and atrial fibrillation as the base rhythm in 1 (8.3%) patient. In G2, 349 isolated and monomorphic ventricular ectopics were identified in 1 (9.1%) patient (Table 2). In all patients, before the start of treatment (G1), an average score of 17% left ventricular mass injury was observed in the evaluation performed using the SS, with a variation between 3% and 39%. In the G1‐FU patients, after 1 year of treatment, an average score of 11% left ventricular mass injury was observed, with a variation between 0% and 21%. Regarding the percentage of injury in G2 patients, an average of 4% LV mass was observed and varied from 0% to 12% (Table 2).

Cardiovascular Magnetic Resonance

In CMR, the presence of LGE was observed in 7 patients (58.3%) in G1. In G1‐FU, there was loss of follow‐up in 2 patients and, of the 10 remaining patients evaluated, 7 (70%) showed delayed enhancement (Table 2). In G2, fibrosis was detected in 2 (18.2%) patients (Figure 1).
Figure 1

Delayed enhancement in cardiovascular magnetic resonance in (A) the medial inferolateral segment and (B) edema in the medial inferolateral.

Both arrows indicate delayed enhancement.

Delayed enhancement in cardiovascular magnetic resonance in (A) the medial inferolateral segment and (B) edema in the medial inferolateral.

Both arrows indicate delayed enhancement. The assessment of left and right ventricular function were analyzed in all patients, and no alterations were observed in right ventricle function (Table 3). A total of 6 patients who presented fibrosis in the pretreatment phase underwent posttreatment evaluation, and 4 (66.75%) presented persistent MF.
Table 3

Description of the Presence of Myocardial Fibrosis and Ejection Fraction in the Acute and Subacute Phases of Patients in 2 Groups Evaluated Using CMR

Delayed enhancementG1 (n=12)G1‐FU (n=10) P value
LGE present7 (58.3%)7 (70.0%)0.042*
LGE absent5 (41.7%)3 (30.0%)
LV ejection fraction, %62.8±7.765.2±8.50.336

Data are described as mean±SD or number (percentage). CMR indicates cardiovascular magnetic resonance; GI, group 1; G1‐FU, group 1 with 1‐year follow‐up; LGE, late gadolinium enhancement; and LV, left ventricle.

Fisher exact test.

One‐way ANOVA post hoc Bonferroni.

Description of the Presence of Myocardial Fibrosis and Ejection Fraction in the Acute and Subacute Phases of Patients in 2 Groups Evaluated Using CMR Data are described as mean±SD or number (percentage). CMR indicates cardiovascular magnetic resonance; GI, group 1; G1‐FU, group 1 with 1‐year follow‐up; LGE, late gadolinium enhancement; and LV, left ventricle. Fisher exact test. One‐way ANOVA post hoc Bonferroni. In the G1‐FU patients, 1 developed MF that was previously undetected. The mean±SD percentage of LGE before treatment was 2.1±3.2. In the follow‐up, the mean±SD was 1.5±1.4. There was no statistical difference (P=0.607; Table 4). A very weak positive correlation was observed between the percentage of injured LV mass and the SS points (ρ=0.004; Figure 2).
Table 4

Evolution of the Presence and Location of Injury on CMR Before and After CMR Treatment

Identification No.Age, ySexDTUAcute phase (n=12)Follow‐up (n=10)
Standard CMRLGE segmentLGE (%)EdemaStandard CMRLGE segmentLGE (%)Edema
0128Male sexTcIVSubepicardiumAnteroseptal basal, anterolateral medial1.8Anterior lateral medial (3.9%, T2 ratio=1.8)Lost to follow‐up
0243Male sexTcIVAbsence of fibrosisNoLost to follow‐up
0360Female sexTcIJunctionalInferoseptal medial2.3No
0474Female sexTcIFocalInferolateral medial2.8NoFocalInferolateral medial1.3No
0551Female sexTcIVAbsence of fibrosisNoAbsence of fibrosisNo
0619Female sexTcIVJunctionalInferoseptal medial0.7NoJunctionalInferoseptal medial0.7No
0722Male sexTcIVJunctional, linear mesocardialInferoseptal medial and apical0.8NoJunctional, linear mesocardialInferoseptal medial and apical2.3No
0835Female sexTcIVFocalInferolateral basal1.1No
0965Female sexTcIVAbsence of fibrosisNoAbsence of fibrosisNo
1021Female sexTcIVJunctional, focalAnteroseptal basal, inferior medial2.5NoJunctional, focalAnteroseptal basal, inferior medial1.4No
1163Male sexMultifocalInferolateral basal, inferior medial10.8Inferolateral medial (6.7%, T2 ratio=1.9)MultifocalLateral, basal, medial, and apical4.7Lateral medial
1290Male sexFocalInferolateral basal1.8NoFocalInferolateral basal1.6No

CMR indicates cardiovascular magnetic resonance; DTU, discrete typing unit; and LGE, late gadolinium enhancement.

Figure 2

Spearman correlation between percentage of LV mass and the Selvester scoring points (P=0.991; ρ=0.004).

LGE indicates late gadolinium enhancement; and LV, left ventricle.

Evolution of the Presence and Location of Injury on CMR Before and After CMR Treatment CMR indicates cardiovascular magnetic resonance; DTU, discrete typing unit; and LGE, late gadolinium enhancement.

Spearman correlation between percentage of LV mass and the Selvester scoring points (P=0.991; ρ=0.004).

LGE indicates late gadolinium enhancement; and LV, left ventricle. Table 4 describes the follow‐up of each patient in the G1/G1‐FU with regard to the presence or absence of delayed enhancement, edema, percentage of delayed enhancement, and location of alterations according to their pattern and myocardial segment.

Discussion

This study demonstrated for the first time that myocardial injury by CMR is present in patients with ACD. All patients were native to the western Brazilian Amazon, and most of the cases were the result of oral transmission attributed to a history of regional fruit juice consumption, such as açaí (Euterpe oleraceae), which is part of the local population’s diet. This new epidemiological profile has been progressively registered in this region, and it is believed that food contamination by triatomines probably occurs when the juices are processed. As a result, this is now considered one of the most important routes of CD infection in Brazil. , , , As recommended by the Brazilian Ministry of Health, all ACD cases should be treated with benznidazole, and there should be a follow‐up of the patient during and after treatment. However, in the Amazon, this is not always the case because cases are rarely monitored, especially because most of them come from remote areas, which prevents patients from returning to the reference clinics. As a result, this compromises the recommendation for follow‐up and contributes to the evolution of the disease. In our study, 56.63% of patients had an abnormal ECG in the acute period of the disease (G1), 25% being ventricular repolarization alteration, followed by left anterior fascicular block, atrial fibrillation, and pre‐excitation. The predominance of the ventricular repolarization alteration variable in G1 demonstrates a possible myocardial impairment in the pretreatment acute phase, which was not found in G1‐FU. This suggests that this alteration, which is related to the acute phase of the disease, may have disappeared as a result of early treatment. The ECG exam is considered the most appropriate, especially when it comes to mild impairment of the heart, and the ventricular repolarization alterations found during the ECG exam are frequent and used in diagnostic screening and are thus considered the primary indicator of the disease. In a report presented by Marques et al, after an outbreak attriuted to the consumption of guava juice at a school in Venezuela, the most common arrhythmias were supraventricular arrhythmias, which occurred in most cases. Ventricular arrhythmias were observed to be less common. During our study, the 24‐hour Holter exam showed that both ventricular extrasystoles and paroxysmal supraventricular tachycardia were found in G1, but subsequently not recorded in G1‐FU. The SS has already been evaluated for testing chronic DC and presents good correlation with CMR; in addition, it may be important for risk stratification in this group of patients. The SS in our study was positive for myocardial injury in G1 and G1‐FU (4.5 points [range, 3–7 points] and 4 points [range, 2–5 points], respectively); however, G2 did not present a score to confirm this alteration (1 point [range, 0–3 points]) because a positive result is given when the score is >3 points. Through CMR, the presence of late enhancement was detected in the patients in G1 and G1‐FU (58.3% and 50%, respectively); however, there was no significant difference in impairment when these patients were evaluated after 1 year of follow‐up. Nonetheless, fibrosis was detected in G2 in only 18.2% of the analyzed group. Fibrosis and myocardial inflammation have been demonstrated in all chronic phases of the disease, with or without heart disease, without ventricular dysfunction, and the amount of fibrosis correlates with the severity of the clinical form, functional class, LV ejection fraction, and LV dilation. CMR has great accuracy in detecting regions of MF in patients with chronic CD. Because we know that these areas of fibrosis can be predictors of the development of malignant arrhythmias, this test becomes a fundamental tool and increases the possibility of detecting this risk early, even with preserved ventricular function. Schmidt et al also reported the potential of CMR in detecting the regions of MF in patients with chronic CD cardiomyopathy and confirmed that this is a potentially valuable tool in the noninvasive risk prediction of these patients suffering sudden death, even in those with LV ejection fraction still preserved. The presence of MF in patients with CD with clinical cardiomyopathy is well established by the use of CMR. Its quantification is related to the Rassi score, a prognostic score validated for CD. According to Uellendahl et al, MF deserves to be investigated using CMR, as it is considered as an independent prognostic factor, which emphasizes its value as a prognostic tool for risk stratification of the disease. In the literature, there is only 1 case report study of ACD using CMR (de Sousa et al ), in which fibrosis was not detected in three different periods after treatment initiation (Day 5, Day 26 and Day 56), only edema, which regressed after treatment. This is the first case series study that used this tool in the evolution, stratification, and follow‐up of cases. Studies reinforce the hypothesis that MF in CD is related to arrhythmias and sudden death, which has already been suggested in electrophysiological evaluation. However, the amount of myocardial injury detected in the evaluation of our patients was considered insufficient to generate arrhythmias of malignant character. One of the limitations of the study is the fact that the patients in G2 were not the same as those evaluated in G1 and G1‐FU because they were recruited after diagnosis, although they were in fact all diagnosed and treated with benznidazole in the same way. The study presents a small number of patients because it is a rare disease and it occurs in sporadic outbreaks in remote regions that are difficult to access.

Conclusions

In this cohort of Amazon autochthonous patients with ACD, myocardial injury by CMR was detected in the pretreatment acute phase and also in the follow‐up 1 year after treatment. In another group of patients with 5.2 years of follow‐up after ACD, only a mildly persistent myocardial injury (18.2%) was detected. The occurrence of myocardial injury in autochthonous patients with ACD in the Amazon reveals the importance of follow‐up in the cardiology clinic. The correlation between fibrosis detected by CMR and SS—a simple and easily accessible test—represents a good tool for the early detection and stratification of patients with myocardial involvement in the acute and subacute phases of CD. This is even more pertinent when one remembers that the Amazon is a region of vast territorial extension with many remote areas and access to CMR may prove difficult for many patients.

Sources of Funding

This study received financial support from Fundação de Amparo à Pesquisa do Estado do Amazonas under the Universal Program Notice N.30/2013.

Disclosures

None.
  16 in total

1.  ECG score correlates with myocardial fibrosis assessed by magnetic resonance: A study in Chagas heart disease.

Authors:  H Rodríguez-Zanella; G Meléndez-Ramírez; Leyli Velázquez; A Meave; E Alexanderson
Journal:  Int J Cardiol       Date:  2015-03-23       Impact factor: 4.164

2.  A detailed guide for quantification of myocardial scar with the Selvester QRS score in the presence of electrocardiogram confounders.

Authors:  Zak Loring; Sreetharan Chelliah; Ronald H Selvester; Galen Wagner; David G Strauss
Journal:  J Electrocardiol       Date:  2011 Sep-Oct       Impact factor: 1.438

3.  Development and validation of a risk score for predicting death in Chagas' heart disease.

Authors:  Anis Rassi; Anis Rassi; William C Little; Sérgio S Xavier; Sérgio G Rassi; Alexandre G Rassi; Gustavo G Rassi; Alejandro Hasslocher-Moreno; Andrea S Sousa; Maurício I Scanavacca
Journal:  N Engl J Med       Date:  2006-08-24       Impact factor: 91.245

4.  Outbreak of acute Chagas disease associated with oral transmission in the Rio Negro region, Brazilian Amazon.

Authors:  Rita de Cássia de Souza-Lima; Maria das Graças Vale Barbosa; José Rodrigues Coura; Ana Ruth Lima Arcanjo; Adelaide da Silva Nascimento; João Marcos Bemfica Barbosa Ferreira; Laylah Kelre Magalhães; Bernardino Cláudio de Albuquerque; Guilherme Alfredo Novelino Araújo; Jorge Augusto de Oliveira Guerra
Journal:  Rev Soc Bras Med Trop       Date:  2013 Jul-Aug       Impact factor: 1.581

5.  Urban outbreak of acute Chagas disease in Amazon region of Brazil: four-year follow-up after treatment with benznidazole.

Authors:  Ana Yecê das Neves Pinto; Alberto Gomes Ferreira; Vera da Costa Valente; Geraldo Saburo Harada; Sebastião Aldo da Silva Valente
Journal:  Rev Panam Salud Publica       Date:  2009-01

6.  Analysis of an acute Chagas disease outbreak in the Brazilian Amazon: human cases, triatomines, reservoir mammals and parasites.

Authors:  Sebastião Aldo da Silva Valente; Vera da Costa Valente; Ana Yecê das Neves Pinto; Maria de Jesus Barbosa César; Marivaldo Picanço dos Santos; Clóvis Omar Sá Miranda; Patrícia Cuervo; Octavio Fernandes
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-12-31       Impact factor: 2.184

7.  Cardiac Magnetic Resonance-Verified Myocardial Fibrosis in Chagas Disease: Clinical Correlates and Risk Stratification.

Authors:  Marly Uellendahl; Maria Eduarda Menezes de Siqueira; Eveline Barros Calado; Roberto Kalil-Filho; Dário Sobral; Clébia Ribeiro; Wilson Oliveira; Silvia Martins; Jagat Narula; Carlos Eduardo Rochitte
Journal:  Arq Bras Cardiol       Date:  2016-11       Impact factor: 2.000

8.  Oral Transmission of Trypanosoma cruzi, Brazilian Amazon.

Authors:  Rosa Amélia G Santana; Maria Graças V B Guerra; Débora R Sousa; Kátia Couceiro; Jessica V Ortiz; Maurício Oliveira; Lucas S Ferreira; Kenny R Souza; Igor C Tavares; Romulo F Morais; George A V Silva; Gisely C Melo; Gabriel M Vergel; Bernardino C Albuquerque; Ana Ruth L Arcanjo; Wuelton M Monteiro; João Marcos B B Ferreira; Marcus V G Lacerda; Henrique Silveira; Jorge Augusto O Guerra
Journal:  Emerg Infect Dis       Date:  2019-01       Impact factor: 6.883

9.  Clinical follow-up of responses to treatment with benznidazol in Amazon: a cohort study of acute Chagas disease.

Authors:  Ana Yecê das Neves Pinto; Vera da Costa Valente; José Rodrigues Coura; Sebastião Aldo da Silva Valente; Angela Cristina Veríssimo Junqueira; Laura Cristina Santos; Alberto Gomes Ferreira; Roberto Cavalleiro de Macedo
Journal:  PLoS One       Date:  2013-05-27       Impact factor: 3.240

10.  Myocardial tissue characterization in Chagas' heart disease by cardiovascular magnetic resonance.

Authors:  Jorge A Torreão; Barbara M Ianni; Charles Mady; Evandro Naia; Carlos H Rassi; Cesar Nomura; José R Parga; Luis F Avila; José A F Ramires; Roberto Kalil-Filho; Carlos E Rochitte
Journal:  J Cardiovasc Magn Reson       Date:  2015-11-18       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.